GlassScriptPhysician profile
Christina M Giles
NPI 1639270317
$3,478.55
in general payments reported to CMS, 2019-2025
22 companies · $588 in 2025
The $588 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $347 · 2021: $225 · 2022: $918 · 2023: $532 · 2024: $494 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471 · Entertainment: $139 · Education: $2.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.52 |
| Entertainment | $139.46 |
| Education | $2.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $529.52 | 2022-2025 | Infuse, Xiidra, Miebo |
| Alcon Vision LLC | $521.31 | 2019-2025 | Total30, Precision 1, Precision7 |
| Notal Vision, INC. | $401.31 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $340.95 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $318.85 | 2020-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $211.25 | 2024-2025 | Xdemvy |
| Optos, INC. | $182.76 | 2019-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Johnson & Johnson Vision Care, INC. | $173.87 | 2019-2025 | |
| Carl Zeiss Meditec, INC. | $156.49 | 2019 | |
| Coopervision INC. | $136.21 | 2019-2025 | Myday Contact Lens |
| Abbvie INC. | $106.98 | 2022 | |
| Biotissue Holdings INC. | $97.75 | 2025 | |
| Novartis Pharmaceuticals Corporation | $59.60 | 2022-2023 | |
| Oasis Medical, INC. | $45.52 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $36.64 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $29.27 | 2022 | |
| Spark Therapeutics, INC. | $27.83 | 2022 | |
| Allergan, INC. | $25.51 | 2021 | |
| Horizon Therapeutics Plc | $22.55 | 2023 | Tepezza |
| Alexion Pharmaceuticals, INC. | $22.51 | 2022 | |
| Plexus Optix, INC. | $18.03 | 2021 | |
| Kala Pharmaceuticals, INC. | $13.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Giles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.